Patient characteristics associated with buprenorphine/naloxone treatment outcome for prescription opioid dependence: Results from a multisite study

Drug and Alcohol Dependence

Volumn 131, Issue 1-3, 2013, Pages 112-118

  Dreifuss, Jessica A ^a,b   Griffin, Margaret L ^a,b   Frost, Katherine ^a   Fitzmaurice, Garrett M ^a,b,c   Potter, Jennifer Sharpe ^a,b,d   Fiellin, David A ^e,f   Selzer, Jeffrey ^g,h,i   Hatch Maillette, Mary ^j   Sonne, Susan C ^k   Weiss, Roger D ^a,b  

^a MCLEAN HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f YALE UNIVERSITY   (United States)

^g Northwell Health   (United States)

^h DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

ⁱ ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^j UNIVERSITY OF WASHINGTON   (United States)

^k MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

more..

Author keywords

Buprenorphine; Drug dependence; Heroin; Opioid analgesics; Predictors; Prescription opioids; Substance abuse; Treatment outcome

Indexed keywords

BUPRENORPHINE PLUS NALOXONE; DIAMORPHINE; NARCOTIC ANALGESIC AGENT; OXYCODONE; PRESCRIPTION DRUG;

ADULT; AGE; ARTICLE; COMPOSITE INTERNATIONAL DIAGNOSTIC INTERVIEW; CONTROLLED STUDY; DEMOGRAPHY; DEPRESSION; DRUG DOSE INCREASE; DRUG USE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MEDICAL HISTORY; MULTICENTER STUDY (TOPIC); NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OPIATE ADDICTION; PAIN; PAIN AND OPIATE ANALGESIC USE HISTORY; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SELF REPORT; TREATMENT OUTCOME;

ADULT; ANALGESICS, OPIOID; BUPRENORPHINE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; NALOXONE; OPIOID-RELATED DISORDERS; PRESCRIPTION DRUGS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84878576685     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2012.12.010     Document Type: Article

References (68)

1. Alterman A.I., Rutherford M.J., Cacciola J.S., McKay J.R., Boardman C.R. Prediction of 7 months methadone maintenance treatment response by four measures of antisociality. Drug Alcohol Depend. 1998, 49:217-223.
2. Alterman A.I., Rutherford M.J., Cacciola J.S., McKay J.R., Woody G.E. Response to methadone maintenance and counseling in antisocial patients with and without major depression. J. Nerv. Ment. Dis. 1996, 184:695-702.
3. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 2000, American Psychiatric Association, Washington, DC.
4. Anton R.F., Oroszi G., O'Malley S., Couper D., Swift R., Pettinati H., Goldman D. An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch. Gen. Psychiatry 2008, 65:135-144.
5. Arfken C.L., Johanson C.E., di Menza S., Schuster C.R. Expanding treatment capacity for opioid dependence with office-based treatment with buprenorphine: national surveys of physicians. J. Subst. Abuse Treat. 2010, 39:96-104.
6. Backmund M., Meyer K., Eichenlaub D., Schutz C.G. Predictors for completing an inpatient detoxification program among intravenous heroin users, methadone substituted and codeine substituted patients. Drug Alcohol Depend. 2001, 64:173-180.
7. Blume A.W., Schmaling K.B., Marlat G.A. Motivating drinking behavior change depressive symptoms may not be noxious. Addict. Behav. 2001, 26:267-272.
8. Bodkin J.A., Zornberg G.L., Lukas S.E., Cole J.O. Buprenorphine treatment of refractory depression. J. Clin. Psychopharmacol. 1995, 15:49-57.
9. Cacciola J.S., Alterman A.I., Rutherford M.J., McKay J.R., Mulvaney F.D. The relationship of psychiatric comorbidity to treatment outcomes in methadone maintained patients. Drug Alcohol Depend. 2001, 61:271-280.
10. Chatham L.R., Rowan-Szal G.A., Joe G.W., Simpson D.D. Heavy drinking, alcohol-dependent vs. nondependent methadone-maintenance clients: a follow-up study. Addict. Behav. 1997, 22:69-80.
11. Dackis C.A., Gold M.S. Pharmacological approaches to cocaine addiction. J. Subst. Abuse Treat. 1985, 2:139-145.
12. Darke S., Ross J., Teesson M., Ali R., Cooke R., Ritter A., Lynskey M. Factors associated with 12 months continuous heroin abstinence: findings from the Australian Treatment Outcome Study (ATOS). J. Subst. Abuse Treat. 2005, 28:255-263.
13. Dean A.J., Bell J., Christie M.J., Mattick R.P. Depressive symptoms during buprenorphine vs. methadone maintenance: findings from a randomised, controlled trial in opioid dependence. Eur. Psychiatry 2004, 19:510-513.
14. Emrich H.M., Vogt P., Herz A. Possible antidepressive effects of opioids: action of buprenorphine. Ann. N. Y. Acad. Sci. 1982, 398:108-112.
15. Favrat B., Rao S., O'Connor P.G., Schottenfeld R. A staging system to predict prognosis among methadone maintenance patients, based on admission characteristics. Subst. Abuse 2002, 23:233-244.
16. Fiellin D.A., Pantalon M.V., Schottenfeld R.S., Gordon L., O'Connor P.G. Manual for Standard Medical Management of Opioid Dependence with Buprenorphine 1999, Yale University, New Haven, CT.
17. Flynn P.M., Joe G.W., Broome K.M., Simpson D.D., Brown B.S. Recovery from opioid addiction in DATOS. J. Subst. Abuse Treat. 2003, 25:177-186.
18. Gelkopf M., Weizman T., Melamed Y., Adelson M., Bleich A. Does psychiatric comorbidity affect drug abuse treatment outcome? A prospective assessment of drug abuse, treatment tenure and infectious diseases in an Israeli methadone maintenance clinic. Isr. J. Psychiatry Relat. Sci. 2006, 43:126-136.
19. George O., Koob G.F. Individual differences in prefrontal cortex function and the transition from drug use to drug dependence. Neurosci. Biobehav. Rev. 2010, 35:232-247.
20. Gerra G., Borella F., Zaimovic A., Moi G., Bussandri M., Bubici C., Bertacca S. Buprenorphine versus methadone for opioid dependence: predictor variables for treatment outcome. Drug Alcohol Depend. 2004, 75:37-45.
21. Goodnough A. Pharmacies Besieged by Addicted Thieves 2011, The New York Times, New York, NY, p. A14.
22. Heinzerling K.G., McCracken J.T., Swanson A.N., Ray L.A., Shoptaw S.J. COMT Val158Met. BDNF Val66Met, and OPRM1 Asn40Asp and methamphetamine dependence treatment response: preliminary investigation. J. Clin. Psychopharmacol. 2012, 32:135-137.
23. Holt L.J., O'Malley S.S., Rounsaville B.J., Ball S.A. Depressive symptoms, drinking consequences, and motivation to change in first time DWI offenders. Am. J. Drug Alcohol Abuse 2009, 35:117-122.
24. Hser Y.I., Grella C.E., Hsieh S.C., Anglin M.D., Brown B.S. Prior treatment experience related to process and outcomes in DATOS. Drug Alcohol Depend. 1999, 57:137-150.
25. Iguchi M.Y., Stitzer M.L. Predictors of opiate drug abuse during a 90-day methadone detoxification. Am. J. Drug Alcohol Abuse 1991, 17:279-294.
26. Joe G.W., Simpson D.D., Broome K.M. Retention and patient engagement models for different treatment modalities in DATOS. Drug Alcohol Depend. 1999, 57:113-125.
27. Joe G.W., Simpson D.D., Sells S.B. Treatment process and relapse to opioid use during methadone maintenance. Am. J. Drug Alcohol Abuse 1994, 20:173-197.
28. Johnson R.E., Chutuape M.A., Strain E.C., Walsh S.L., Stitzer M.L., Bigelow G.E. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N. Engl. J. Med. 2000, 343:1290-1297.
29. Khantzian E.J. The self-medication hypothesis of addictive disorders: focus on heroin and cocaine dependence. Am. J. Psychiatry 1985, 142:1259-1264.
30. Khantzian E.J. The self-medication hypothesis of substance use disorders: a reconsideration and recent applications. Harv. Rev. Psychiatry 1997, 4:231-244.
31. Mancino M., Curran G., Han X., Allee E., Humphreys K., Booth B.M. Predictors of attrition from a national sample of methadone maintenance patients. Am. J. Drug Alcohol Abuse 2010, 36:155-160.
32. Marlatt G.A. Introduction. Addictive Behaviors. 1997, American Psychological Association, Washington, DC, pp. xi-xxv. G.A. Marlatt, G.R. VandenBos (Eds.).
33. Marsch L.A., Stephens M.A., Mudric T., Strain E.C., Bigelow G.E., Johnson R.E. Predictors of outcome in LAAM, buprenorphine, and methadone treatment for opioid dependence. Exp. Clin. Psychopharmacol. 2005, 13:293-302.
34. McLellan A.T. Patient characteristics associated with outcome. Research on the Treatment of Drug Addiction: State of the Art 1983, 500-529. US Government Printing Office, Washington, DC. J.R. Cooper, F. Altman, B.S. Brown, D. Czechowicz (Eds.).
35. McLellan A.T., Alterman A.I., Metzger D.S., Grissom G.R., Woody G.E., Luborsky L., O'Brien C.P. Similarity of outcome predictors across opiate, cocaine, and alcohol treatments: role of treatment services. J. Consult. Clin. Psychol. 1994, 62:1141-1158.
36. Meier B. Pain Killer: A " Wonder" Drug's Trail of Addiction and Death 2003, Rodale, Emmaus, PA.
37. Moore B.A., Fiellin D.A., Barry D.T., Sullivan L.E., Chawarski M.C., O'Connor P.G., Schottenfeld R.S. Primary care office-based buprenorphine treatment: comparison of heroin and prescription opioid dependent patients. J. Gen. Intern. Med. 2007, 22:527-530.
38. Murphy S.A., Lynch K.G., Oslin D., McKay J.R., TenHave T. Developing adaptive treatment strategies in substance abuse research. Drug Alcohol Depend. 2007, 88(Suppl. 2):S24-S30.
39. Newton T.F., De La Garza R., Kalechstein A.D., Tziortzis D., Jacobsen C.A. Theories of addiction: methamphetamine users' explanations for continuing drug use and relapse. Am. J. Addict. 2009, 18:294-300.
40. O'Connor P.G., Oliveto A.H., Shi J.M., Triffleman E.G., Carroll K.M., Kosten T.R., Rounsaville B.J., Pakes J.A., Schottenfeld R.S. A randomized trial of buprenorphine maintenance for heroin dependence in a primary care clinic for substance users versus a methadone clinic. Am. J. Med. 1998, 105:100-105.
41. Pani P.P., Maremmani I., Pirastu R., Tagliamonte A., Gessa G.L. Buprenorphine: a controlled clinical trial in the treatment of opioid dependence. Drug Alcohol Depend. 2000, 60:39-50.
42. Pantalon M.V., Fiellin D.A., Schottenfeld R.S., Gordon L., O'Connor P.G. Manual for Enhanced Medical Management of Opioid Dependence with Buprenorphine 1999, Yale University, New Haven, CT.
43. Peles E., Schreiber S., Adelson M. 15-Year survival and retention of patients in a general hospital-affiliated methadone maintenance treatment (MMT) center in Israel. Drug Alcohol Depend. 2010, 107:141-148.
44. Petry N.M., Bickel W.K. Therapeutic alliance and psychiatric severity as predictors of completion of treatment for opioid dependence. Psychiatr. Serv. 1999, 50:219-227.
45. Petry N.M., Bickel W.K. Gender differences in hostility of opioid-dependent outpatients: role in early treatment termination. Drug Alcohol Depend. 2000, 58:27-33.
46. Rao S.R., Broome K.M., Simpson D.D. Depression and hostility as predictors of long-term outcomes among opiate users. Addiction 2004, 99:579-589.
47. Resnick R.B., Resnick E., Galanter M. Buprenorphine responders: a diagnostic subgroup of heroin addicts?. Prog. Neuropsychopharmacol. Biol. Psychiatry 1991, 15:531-538.
48. Saxon A.J., Wells E.A., Fleming C., Jackson T.R., Calsyn D.A. Pre-treatment characteristics, program philosophy and level of ancillary services as predictors of methadone maintenance treatment outcome. Addiction 1996, 91:1197-1209.
49. Schottenfeld R.S., Pakes J.R., Kosten T.R. Prognostic factors in Buprenorphine- versus methadone-maintained patients. J. Nerv. Ment. Dis. 1998, 186:35-43.
50. Sigmon S.C. Characterizing the emerging population of prescription opioid abusers. Am. J. Addict. 2006, 15:208-212.
51. Simpson D.D., Joe G.W., Rowan-Szal G.A. Drug abuse treatment retention and process effects on follow-up outcomes. Drug Alcohol Depend. 1997, 47:227-235.
52. Soyka M., Zingg C., Koller G., Kuefner H. Retention rate and substance use in methadone and buprenorphine maintenance therapy and predictors of outcome: results from a randomized study. Int. J. Neuropsychopharmacol. 2008, 11:641-653.
53. Stenbacka M., Beck O., Leifman A., Romelsjo A., Helander A. Problem drinking in relation to treatment outcome among opiate addicts in methadone maintenance treatment. Drug Alcohol Rev. 2007, 26:55-63.
54. Strain E.C., Stitzer M.L., Liebson I.A., Bigelow G.E. Useful predictors of outcome in methadone-treated patients: results from a controlled clinical trial with three doses of methadone. J. Maint. Addict. 1998, 1:15-28.
55. Substance Abuse and Mental Health Services Administration The TEDS Report: Substance Abuse Treatment Admissions Involving Abuse of Pain Relievers: 1998 and 2008. 2010, Office of Applied Studies, Rockville, MD.
56. Substance Abuse and Mental Health Services Administration Results from the 2010 National Survey on Drug Use and Health: Volume I. Summary of National Findings. NSDUH Series H-41. 2011, Substance Abuse and Mental Health Services Administration, Rockville, MD.
57. Sullivan L.E., Moore B.A., O'Connor P.G., Barry D.T., Chawarski M.C., Schottenfeld R.S., Fiellin D.A. The association between cocaine use and treatment outcomes in patients receiving office-based buprenorphine/naloxone for the treatment of opioid dependence. Am. J. Addict. 2010, 19:53-58.
58. Teesson M., Mills K., Ross J., Darke S., Williamson A., Havard A. The impact of treatment on 3 years' outcome for heroin dependence: findings from the Australian Treatment Outcome Study (ATOS). Addiction 2008, 103:80-88.
59. Torrens M., Castillo C., Perez-Sola V. Retention in a low-threshold methadone maintenance program. Drug Alcohol Depend. 1996, 41:55-59.
60. Weiss R.D., Potter J.S., Copersino M.L., Prather K., Jacobs P., Provost S., Chim D., Selzer J., Ling W. Conducting clinical research with prescription opioid dependence: defining the population. Am. J. Addict. 2010, 19:141-146.
61. Weiss R.D., Potter J.S., Fiellin D.A., Byrne M., Connery H.S., Dickinson W., Gardin J., Griffin M.L., Gourevitch M.N., Haller D.L., Hasson A.L., Huang Z., Jacobs P., Kosinski A.S., Lindblad R., McCance-Katz E.F., Provost S.E., Selzer J., Somoza E.C., Sonne S.C., Ling W. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. Arch. Gen. Psychiatry 2011, 68:1238-1246.
62. Weiss R.D., Potter J.S., Provost S.E., Huang Z., Jacobs P., Hasson A., Lindblad R., Connery H.S., Prather K., Ling W. A multi-site, two-phase, Prescription Opioid Addiction Treatment Study (POATS): rationale, design, and methodology. Contemp. Clin. Trials 2010, 31:189-199.
63. Wells-Parker E., Dill P., Williams M., Stoduto G. Are depressed drinking/driving offenders more receptive to brief intervention?. Addict. Behav. 2006, 31:339-350.
64. Wells-Parker E., Williams M. Enhancing the effectiveness of traditional interventions with drinking drivers by adding brief individual intervention components. J. Stud. Alcohol 2002, 63:655-664.
65. Williamson A., Darke S., Ross J., Teesson M. The effect of baseline cocaine use on treatment outcomes for heroin dependence over 24 months: findings from the Australian Treatment Outcome Study. J. Subst. Abuse Treat. 2007, 33:287-293.
66. World Health Organization Composite International Diagnostic Interview (CIDI): Core Version 2.1 1997 January, World Health Organization, Geneva, Switzerland.
67. Zacny J.P., Gutierrez S. Within-subject comparison of the psychopharmacological profiles of oral hydrocodone and oxycodone combination products in non-drug-abusing volunteers. Drug Alcohol Depend. 2009, 101:107-114.
68. Zacny J.P., Lichtor S.A. Within-subject comparison of the psychopharmacological profiles of oral oxycodone and oral morphine in non-drug-abusing volunteers. Psychopharmacol. (Berl.) 2008, 196:105-116.